

ASX/Media Release

Grant of Divisional Patent in US

5 May 2006, Melbourne: The Board of Directors of EQiTX Limited (ASX:EQX) announced today that the United States Patent and Trademarks Office has granted a divisional patent claiming epitopes being used in the development of lipopeptide vaccines by its investee company, VacTX Pty Ltd.

The patent (US 7,037,507) is the second divisional to be issued from the granted US patent US 6,685,947. This patent family claims a number of T helper cell epitopes derived from the fusion protein of canine distemper virus and their use in inducing immune responses. This technology was developed by the Cooperative Research Centre for Vaccine Technology and is combined with its lipopeptide technology to create novel synthetic vaccines.

VacTX has exclusive, worldwide rights to exploit the T helper cell epitope and lipopeptide technologies to develop synthetic vaccines for human applications. The VacTX technology has the potential to produce safe and effective vaccines to prevent or treat conditions including infections, cancer, allergy and autoimmune diseases.

Inquiries

Sue MacLeman
Chief Executive Officer
EQiTX Limited
0437 211 200

Rudi Michelson
Monsoon Communications
0411 402 737

About EQiTX (www.EQiTX.com)

EQiTX Limited (ASX:EQX) is a publicly listed Australian biotechnology company with interests in the areas of chronic diseases and age-related conditions. EQiTX is developing a portfolio of technologies to a stage where they will be of commercial interest to multinational pharmaceutical and biotechnology companies. The company's two main programs are the ZingoTX project to develop pharmacologically active compounds for pain management, and the VacTX project to develop and commercialise novel synthetic immunotherapeutics against a range of human conditions, including infectious diseases, cancer, allergies and autoimmune diseases.

EQiTX Limited

Level 1, 123 Camberwell Rd
Hawthorn East VIC 3123,
Phone (+61 3) 98119998
Fax: (+61 3) 98134259

Email: info@eqitx.com
www.eqitx.com

ABN: 50 009 188 694